news
Ivermectin shows activity against COVID-19 in cell cultures
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
List view / Grid view
Covid-19
news
Novel COVID-19 vaccine shows efficacy in mice
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news
Biotech and academia collaborate on intranasal COVID-19 vaccine development
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
news
AI technology to screen existing drugs for use against COVID-19
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
news
COVID-19 update: funding for treatments and vaccines
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
news
Free access to AI Clinical Research Navigator tool for COVID-19 researchers
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
Johnson & Johnson identifies lead COVID-19 vaccine candidate
A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
news
Novel antiviral compound proposed as COVID-19 therapeutic
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
article
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
news
Collaboration initiated to develop COVID-19 immunotherapy
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
